louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03398616: Regulation of Retinal Bloodflow Pressure
Official title: Regulation of Retinal Blood Flow in Response to an Experimental Increase in Intraocular Pressure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Retinal Bloodflow
Keywords: Retinal Bloodflow Pressure
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2018-01-12
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 16 healthy subjects

Brief summary: Autoregulation is defined as the ability of a vascular bed to adapt its vascular resistance to changes in perfusion pressure. In the eye, several studies have reported that retinal blood flow is autoregulated over a wide range of ocular perfusion pressures. Large scale studies have shown that reduced ocular perfusion pressure is an important risk factor for the prevalence, the incidence and the progression of primary open angle glaucoma. There is also evidence that autoregulation is impaired in patients with primary open angle glaucoma.

To gain more insight into these phenomena in humans is the primary goal of the present study.

The present study aims to investigate the pressure/flow relationship as a measure for retinal blood flow autoregulation during an experimental increase in intraocular pressure by the use of the suction cup technique. Retinal blood flow will be measured by Doppler OCT.


Eligibility criteria: Inclusion Criteria:

* Men and women aged between 18 and 35 years
* Non-smokers
* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant
* Normal ophthalmic findings, ametropy \< 1 Dpt.

Exclusion Criteria:- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study

* Treatment in the previous 3 weeks with any drug (except contraceptives)
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Blood donation during the previous 3 weeks
* Pregnancy, planned pregnancy or lactating

Primary outcomes:
measure: Retinal pressure-flow-relationship as assessed with FDOCT
timeFrame: 01.02.2018-31.12.2018
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Clinical Pharmacology, Medical University of Vienna
Study officials:
References:
citation: Puchner S, Schmidl D, Ginner L, Augustin M, Leitgeb R, Szegedi S, Stjepanek K, Hommer N, Kallab M, Werkmeister RM, Schmetterer L, Garhofer G. Changes in Retinal Blood Flow in Response to an Experimental Increase in IOP in Healthy Participants as Assessed With Doppler Optical Coherence Tomography. Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):33. doi: 10.1167/iovs.61.2.33.
Clinical trial NCT06751316: Clinical and Radiographic Evaluation of MTA Pulpotomy Versus Conventional Pulpectomy in Primary Molars With Irreversible Pulpitis
Official title: Clinical and Radiographic Evaluation of MTA Pulpotomy Versus Conventional Pulpectomy in Primary Molars With Irreversible Pulpitis: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Decayed Primary Molars With Irreversible Pulpitis
Keywords: MTA pulpotomy
Pulpectomy
Decayed primary molars
Irreversible pulpitits
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 42
Sex: ALL
Minimum age (years): 4
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to compare between MTA Pulpotomy (Removal of coronal pulp tissue, placing MTA and covering with Stainless steel crown) Versus Conventional Pulpectomy (Removal of radicular pulp tissue, placing Zinc Oxide/Eugenol and covering with Stainless steel crown) in irreversible pulpitis in primary second molars.


Eligibility criteria: Inclusion Criteria:

* Patients:
* Aged 4-7 years, cooperative, in good general health and medically within normal
* Teeth:
* Restorable mandibular second primary molars.
* History of irreversible pulpitis.
* Preoperative radiograph:
* Absence of periapical or inter-radicular radiolucency.
* Absence of widening of periodontal ligaments (PDL) space.
* Absence of internal or external root resorption.

Exclusion Criteria:

* Patients:
* With systemic disorders.
* Physical or mental disabilities.
* Unable to attend follow- up visits.
* Refusal of Participation.
* Refusal to sign the informed consent.
* Teeth:
* Previously accessed teeth.
* Mobile mandibular second primary molar.
* Swelling in the vestibule or on palpation.
* Pain on percussion.

Primary outcomes:
measure: • rate of clinical success
timeFrame: 12 months
Secondary outcomes:
measure: • rate of radiographic success
timeFrame: 12 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT06009016: Inflammation and Coagulation Factors for Predicting Cerebral Edema After SAH
Official title: Inflammation and Coagulation Factors in Cerebrospinal Fluid for Predicting Persistent Cerebral Edema After Subarachnoid Hemorrhage
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Inflammation
Coagulation and Hemorrhagic Disorders
Cerebral Edema
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-08-24
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subarachnoid hemorrhage patients admitted to our neurosurgery department with modified Fisher Scale 3-4, with a confirmed radiographic diagnosis. Age range from 20-80.

Brief summary: Explore the role of Inflammation and coagulation factors in cerebrospinal fluid for predicting persistent cerebral edema after subarachnoid hemorrhage


Eligibility criteria: Inclusion Criteria:

* Subarachnoid hemorrhage patients admitted to our neurosurgery department with modified Fisher Scale 3-4, with a confirmed radiographic diagnosis.

Exclusion Criteria:

* Angiogram-negative patients, patients with a history of trauma or previous brain injury (stroke, hemorrhage, surgery et al. which left associated chronic changes on CT), arteriovenous malformation, radiological data lost, accompany with serious comorbidities before subarachnoid hemorrhage onset (such as coagulation defects, uncontrollable hypertension, and arrhythmia et.al.), initial radiological data performed more than 3 days after SAH onset

Primary outcomes:
measure: Cerebral edema after subarachnoid hemorrhage
timeFrame: At 3 and 7days after SAH onset
measure: Outcome at 3 months after subarachnoid hemorrhage
timeFrame: 3 months after subarachnoid hemorrhage
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Second affiliated hospital of Zhejiang University, School of Medicine
state: Zhejiang
Study officials:
References:
Clinical trial NCT00204516: Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
Official title: Pilot Study of Intradermal Vaccination of Melanoma Patients With a Fixed Combination of mRNAs Compared to an Individualized Selection After Analysis of Antigen Expression in Tumor Tissue
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Malignant Melanoma
Keywords: vaccination
mRNA
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: German Research Foundation
First posted: 2005-09-20
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the vaccination protocol is to induce specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigen.

Detailed description: vaccination protocol to induce clinically specific immune responses against melanoma associated antigens by intradermal injections of mRNA coding for the corresponding antigens. Half of patients is treated with mRNA coding for Melan-A, Mage-A1, Mage-A3, Survivin, GP100 and Tyrosinase. The other half of patients is treated with an individualized selection of mRNAs after analysis of overexpressed melanoma antigens in autologous tumor tissue. GM-CSF is used as an adjuvants. Phase I/II clinical trial to analyse safety and immune responses in stage III/IV melanoma patients.

Eligibility criteria: Inclusion Criteria:

* malignant melanoma stage III/IV
* fresh frozen tumor tissue available
* informed consent given
* Karnofsky \>= 70%

Exclusion Criteria:

* brain metastasis
* parallel chemotherapy
* systemic treatment with glucocorticoids
* other malignancies

Primary outcomes:
measure: Tolerability
timeFrame: every 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: Department of Dermatology, University of Tuebingen
Study officials:
affiliation: University of Tuebingen, Department of Dermatology
name: Claus Garbe, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04697316: Transcranial Direct Current Stimulation (tDCS) as a Cognitive Functioning Enhancement Treatment for ADHD Patients Compared to Healthy Controls
Official title: Transcranial Direct Current Stimulation (tDCS) as a Cognitive Functioning Enhancement Treatment for ADHD Patients Compared to Healthy Controls
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transcranial Direct Current Stimulation
Lead sponsor: Hebrew University of Jerusalem
Sponsor class: OTHER
First posted: 2021-01-06
Enrollment: 63
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will examine the possible effects of tDCS (Transcranial Direct Current Stimulation) treatment to the left DLPFC on cognitive functions which were found to be deficient amongst ADHD patients. The study will include 100 subjects, 50 of whom diagnosed with ADHD. Subjects will complete the ASRS questionnaire to measure ADHD symptoms severity. Next, subjects will complete a series of cognitive tasks, after which they will receive either tDCS treatment or a sham treatment. Finally, subjects will repeat the cognitive tasks. Later that day, a telephonic follow up will take place. ADHD symptoms will be assessed again the next day.


Eligibility criteria: Inclusion Criteria:Participation criteria for healthy participants

1. Right hand dominance.
2. No psychiatric nor neural diagnosis.
3. Participants must be able to comprehend the study's procedure and sign an informed consent.

Participation criteria for ADHD diagnosed participants

1. ADHD diagnosis (according to DSM V).
2. Right hand dominance.
3. Participants must be able to comprehend the study's procedure and sign an informed consent.
4. Participants who regularly use Methylphenidate will be required to avoid the medication for 24 hours prior to study and 12 hours post study.

   -

Exclusion Criteria:

* a. Other psychiatric diagnoses (additional to ADHD). b. Drug use (excluding Methylphenidate). c. Neurological disorders. d. Pacemaker, Insulin pump

Primary outcomes:
measure: N-back
timeFrame: through study completion
measure: Stroop
timeFrame: through study completion, up to 1 hour after treatment
measure: Stop-signal
timeFrame: through study completion, up to 1 hour after treatment
measure: Time Reproduction task
timeFrame: through study completion, up to 1 hour after treatment
measure: Continuous Performance Task
timeFrame: through study completion, up to 1 hour after treatment
measure: Navon task
timeFrame: through study completion, up to 1 hour after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hebrew University of Jerusalem
Study officials:
References:
Clinical trial NCT06818916: Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children with Neuroblastoma
Official title: Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children with Neuroblastoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Delayed Platelet Engraftment
Neuroblastoma
Autologous Hematopoietic Stem Cell Transplantation
Keywords: Hetrombopag
delayed platelet engraftment
neuroblastoma
pediatrics
autologous hematopoietic stem cell transplantation
Lead sponsor: Beijing Children's Hospital
Sponsor class: OTHER
First posted: 2025-02-11
Enrollment: 30
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is:

· Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \&gt; 100\*10\^9/L.


Eligibility criteria: Inclusion Criteria:

* Age\<18 years old;
* Diagnosed as neuroblastoma;
* ECOG ≤ 2;
* First time receiving autologous hematopoietic stem cell transplantation;
* The subjects or their legal guardians agree to participate and sign the informed consent form.

Exclusion Criteria:

* ALT/AST \> 3 ULN, or TBIL \> 1.5 ULN;
* Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;
* Suffering from thromboembolic diseases;
* Other situations that are not suitable for inclusion in the study determined by researchers.

Primary outcomes:
measure: Accumulated platelet engraftment rate
timeFrame: From enrollment to 60 days post-transplant
Secondary outcomes:
measure: Number of platelet transfusions
timeFrame: From enrollment to 60 days post-transplant
measure: Time to platelet engraftment
timeFrame: From enrollment to 60 days post-transplant
measure: progression-free survival (PFS)
timeFrame: From enrollment to 60 days post-transplant
measure: Adverse events
timeFrame: From medication to 30 days after discontinuation
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University
Study officials:
References:
Clinical trial NCT02093416: Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study
Official title: Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obesity
Keywords: Obesity
Leptin
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2014-03-21
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Males and Females undergoing endoscopy

Brief summary: Prospective cohort study evaluating the role of leptin receptors in the bariatric surgical population compared with non obese controls. Additionally serum levels of leptin, ghrelin, motilin and PYY will be compared amongst the different BMI classes and a quality of life questionnaire completed by all participants.

The hypothesis is that obese individuals have lower leptin receptors in enterocytes which is partially responsible for the higher serum leptin levels without appropriate control of satiety.


Eligibility criteria: Inclusion Criteria:

* Endoscopic Intervention

Exclusion Criteria:

* 18 years of age or older
* No acute GI bleeding

Primary outcomes:
measure: PCR test for Leptin Receptors
timeFrame: 1 week
Secondary outcomes:
measure: ELISA test for ghrelin, motilin, leptin and PYY
timeFrame: 1 week
measure: IWQOL lite questionnaire
timeFrame: 1 week
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh/UPMC Presby
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Jennifer L Seminerio, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00065416: Evaluating Therapeutic Massage for Chronic Neck Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Neck Pain
Cervicalgia
Keywords: neck pain
cervicalgia
massage
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2003-07-23
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will provide the basis for a full-scale trial to evaluate the effectiveness and safety of therapeutic massage for chronic neck pain (CNP).

Detailed description: Neck pain is one of the most common problems affecting the health of Americans and is a leading reason for using complementary or alternative medical (CAM) therapies. Therapeutic massage is one of the most popular CAM treatments for neck pain, but little is known about its effectiveness. This study will lay the groundwork for a full-scale trial that evaluates the effectiveness of therapeutic massage for chronic neck pain.

The study will involve two phases. During Phase I, researchers will develop and pre-test key components for a randomized clinical trial. In Phase II, the safety and efficacy of massage for CNP will be evaluated. The changes in symptoms, function, and quality of life in massage and self care groups will be evaluated midway through treatment, at the end of treatment and at 6 months post randomization.

Eligibility criteria: The inclusion and exclusion criteria will be developed through consultation with a medical expert on neck pain and several massage consultants

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Group Health Cooperative, Center for Health Studies
state: Washington
Study officials:
affiliation: Group Health Cooperative Center for Health Studies
name: Karen J Sherman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06392516: Ketoacid Analogues Intradialytic Effect on Inflammation
Official title: Effect of Intradialytic Administration of Ketoacid Analogues on Inflammatory Parameters in Patients Undergoing Chronic Hemodialysis Twice a Week
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Hemodialysis Complication
Keywords: ketoacid analogues
inflammation
hemodialysis
Lead sponsor: RSUP Fatmawati
Sponsor class: OTHER
First posted: 2024-04-30
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: intervention and control
Primary purpose: TREATMENT

Brief summary: this study tries to measure the effect of intradialytic ketoacid analogues on inflammatory parameters

Detailed description: this study will measure inflammation parameters:

* interleukin 6
* malnutrition inflammation score
* neutrophil lymphocyte ratio
* monocyte lymphocyte ratio
* thrombocyte lymphocyte ratio

the duration of intervention is 12 weeks

Eligibility criteria: Inclusion Criteria:

* patient who undergo hemodialysis two times a week

Exclusion Criteria:

* travelling hemodialysis
* acute conditions
* HIV patient
* acute infection
* stroke and immobilized patient

Primary outcomes:
measure: interleukin-6
timeFrame: 12 weeks
measure: malnutrition inflammation score
timeFrame: 12 weeks
measure: neutrophil lymphocyte ratio
timeFrame: 12 weeks
measure: monocyte lymphocyte ratio
timeFrame: 12 weeks
measure: thrombocyte lymphocyte ratio
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jakarta
country: Indonesia
facility: RSUP Fatmawati
state: Jakarta Selatan
Study officials:
References:
Clinical trial NCT04069416: Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria
Official title: Salvage Living Donor Liver Transplantation for HCC Beyond All Criteria Yield Equivalent Results to Milan Criteria in High Prevalence Young HCC Patients Country.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hcc
Keywords: liver transplant
HCC
Extended milan
Living donor liver transplantation
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-08-28
Enrollment: 241
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients were divided according to the pre-transplant radiological findings of HCC nodules number and sizes into 3 groups:

Group I: comprised 175 patients who fall within the Milan criteria. Group II: included 36 patients who fall within up-to-7 criteria (the sum of the number of the tumors and diameter of the largest tumor not exceeding 7cm) Group III: included 30 patients beyond up-to-7 criteria and will be termed beyond all criteria (BAC).

Brief summary: The present study aims to evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients.

Detailed description: Introduction:

HEPATOCELLULAR CARCINOMA (HCC) is the second leading cause of cancer mortality worldwide. Living donor liver transplantation (LDLT) for HCC patients has emerged as a rewarding therapy for a cure and a successful alternative where a Deceased donor liver transplantation (DDLT) program is lacking. Therefore, trials for careful expansion to Milan criteria have been adopted.

Aim of the study:

To evaluate the impact of expanding criteria beyond Milan on tumor recurrence and patient survival that will help identify the best selection criteria for HCC transplanted patients

Eligibility criteria: Inclusion Criteria:

* All patient transplanted for HCC eligible for transplant (no vascular invasion-no extra hepatic metastasis)
* age\>18y

Exclusion Criteria:

* other etiology for liver transplant rather than HCC
* patient not fit for surgery
* age \>70y

Primary outcomes:
measure: HCC recurrence
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: